ADA: Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show
Clinical Catch-up for June 10-14
Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
New Biktarvy spot puts Gilead in top TV-spending ranks, right behind AbbVie and Pfizer
Novo Nordisk's semaglutide is headed toward a Lilly showdown. Will Novo speed it up?
Novo’s next big diabetes bet heads to regulators
7 drugs that raised eyebrows in Q3
Lilly's under-pressure Trulicity scores with first-of-its-kind cardio outcomes win
Novo Nordisk boosts its GLP-1 score with yet more evidence for crucial semaglutide pill
Viagra no more: The changing face of drug ads on TV